sPLA2 Inhibition to Decrease Enzyme Release After PCI Trial (SPIDER-PCI)
sPLA2 Inhibition to Decrease Enzyme Release After PCI (SPIDER-PCI) Trial
As evidence accumulates that atherogenesis or Coronary Artery Disease (CAD) may not be simply a disorder of lipid metabolism, but an inflammatory disease, the focus of treatment has shifted. A-002 or Varespladib is an anti-inflammatory drug for treatment of chronic and acute diseases. It acts by inhibiting secretory phospholipase A2 (sPLA2 ) - one of a family of enzymes leading to inflammation - which may be important in: 1) the development of atherosclerosis and 2) the increase in occurence of cardiovascular events after angioplasty. Previous studies have demonstrated that sPLA2: 1) facilitates the pro-atherogenic effects of low-density (LDL or bad cholesterol) and 2) increased levels post-angioplasty correlate with an increased risk of events at followup contact. Therefore this study proposes to investigate the ability of A-002 to prevent or reduce myocardial damage after angioplasty by inhibiting the cascade of inflammatory mediators.
Substudy - Subjects who agree will also have a vascular ultrasound 24h post-PCI to assess endothelial function.
연구 개요
상세 설명
Tissue injury after angioplasty is likely due to micro-emboli from mechanical trauma to a thrombotic lesion during angioplasty. In response to the ischemia sPLA2, possibly localized within atherosclerotic vascular tissue as well as from macrophages and monocytes, is released. Following ischemia-induced release, sPLA2 can bind to ischemically challenged cardiomyocytes and adversely affect their survival either directly through toxic effects on cardiomyocytes or indirectly by facilitating inflammation. It may be possible through sPLA2 inhibition to salvage non-lethally jeopardized cells following an ischemic episode thereby reducing the infarcted area and amount of tissue damage. Previous studies in patients with unstable angina support this hypothesis, and conclude that sPLA2 levels can be used to predict clinical outcomes. We hypothesize that sPLA2 inhibition with A-002 will reduce myocardial injury post-angioplasty.
Substudy - Peripheral vascular ultrasound should be done prior to receiving study drug and 24h post-PCI. Coronary endothelial function will be assessed at the time of PCI.
연구 유형
등록 (예상)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5G 2C4
- Toronto General Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Men or women ≥ 18 years of age undergoing elective PCI, with or without stenting
Exclusion Criteria:
- ST elevation MI or any troponin elevation (non-STEMI) within preceding 10days
- Elevation of CK-MB or troponin I at baseline
- Recent (4 weeks) coronary bypass surgery
- NYHA class III-IV heart failure
- Left ventricular ejection fraction < 0.30
- Severe valvular heart disease
- Chronic inflammatory disease (e.g., lupus, rheumatoid arthritis, inflammatory bowel disease), or patients receiving steroid drugs
- Presence of severe liver disease with cirrhosis
- Recent active hepatitis
- Active chronic hepatitis
- ALT or AST > 3 × upper limit of normal (ULN)
- Biliary obstruction with hyperbilirubinemia (total bilirubin > 2 × ULN)
- Moderate or severe renal impairment (creatinine > 1.5 × ULN)
- Nephrotic syndrome or subjects undergoing dialysis
- Uncontrolled diabetes (HbA1c > 11% 1 month prior to screening)
- Initiation of statin therapy within 30 days
- Inability to provide consent.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: Control
Subjects take 2 tablets BID.
Placebo tablets are identical to active medication.
|
250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.
|
|
실험적: Varespladib (A-002)
Subjects take 250mg tablets BID beginning 3-5 days pre-angioplasty and for 5 days post-angioplasty.
|
250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
The primary endpoint will be incidence of myocardial injury as evidenced by elevation of CK-MB or troponin I above the upper limit of normal.
기간: 8 hours and 18-24 hours post-angioplasty
|
8 hours and 18-24 hours post-angioplasty
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
A secondary endpoint will be occurrence of elevation of CK-MB or troponin I above the upper limit of normal.
기간: 8 and 18-24 hours post-angioplasty
|
8 and 18-24 hours post-angioplasty
|
|
A secondary endpoint will be occurrence of any major adverse cardiac events (MACE).
기간: 30 days post-angioplasty
|
30 days post-angioplasty
|
|
A secondary outcome will be serum sPLA2 activity.
기간: 5-7 days post-angioplasty
|
5-7 days post-angioplasty
|
공동 작업자 및 조사자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- SPIDER001
- A Sub-study of SPIDER-PCI
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .